Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Matching Placebo Patch Clear all
Completed Phase 4 Interventional Results available

Raloxifene and Rimostil for Perimenopause-Related Depression

NCT00030147
View directory record Official record
Conditions
Perimenopausal Depression, Depression
Interventions
Raloxifene, Rimostil, Transdermal Estradiol, Placebo skin patch and placebo tablets
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
40 Years to 60 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging

NCT01664741
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicotine patch - transdermal, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 4 Interventional

Dupilumab in the Treatment of Keloids

NCT04988022
View directory record Official record
Conditions
Keloid
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

NCT02068846
View directory record Official record
Conditions
HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion
Interventions
Ciprofloxacin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 2Phase 3 Interventional

Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis

NCT00640939
View directory record Official record
Conditions
Rotator Cuff Tendonitis, Bicipital Tendonitis, Subdeltoid Bursitis of the Shoulder, Subacromial Bursitis of the Shoulder, Medial Epicondylitis of the Elbow, Lateral Epicondylitis of the Elbow, DeQuervain's Tenosynovitis of the Wrist
Interventions
diclofenac sodium, Matching Placebo
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT02042196
View directory record Official record
Conditions
Menopause, Aging
Interventions
KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 20, 2026, 10:32 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06065670
View directory record Official record
Conditions
Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 20, 2026, 10:32 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00499863
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate transdermal system, Placebo
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

US Cycle Control and Blood Pressure Study

NCT00920985
View directory record Official record
Conditions
Contraception
Interventions
Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 20, 2026, 10:32 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
View directory record Official record
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

NCT01213524
View directory record Official record
Conditions
Tobacco Use Disorder, Schizophrenia
Interventions
sensorimotor replacement, 42 mg transdermal nicotine replacement, Placebo transdermal nicotine, usual brand smoking
Behavioral · Drug · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years to 99 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 20, 2026, 10:32 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 4 Interventional Results available

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

NCT04112368
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 20, 2026, 10:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Garetosmab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

NCT02792218
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
56
States / cities
Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 20, 2026, 10:32 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
treprostinil diethanolamine, placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 4 Interventional Results available

Combination Nicotine Replacement for Alcoholic Smokers

NCT00064844
View directory record Official record
Conditions
Smoking, Alcoholism
Interventions
Cognitive Behavior Therapy for alcohol and smoking cessation, Nicoderm CQ nicotine patch, Placebo gum, Nicotine gum - Nicorette®
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Newington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

ELITE: Early Versus Late Intervention Trial With Estradiol

NCT00114517
View directory record Official record
Conditions
Atherosclerosis
Interventions
17B-estradiol, Placebo
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
Female only
Enrollment
643 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 20, 2026, 10:32 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

NCT05741476
View directory record Official record
Conditions
Allergy, Peanut
Interventions
DBV712, Placebo
Drug · Other
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 7 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 20, 2026, 10:32 PM EDT
Completed Phase 3 Interventional

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain

NCT00869180
View directory record Official record
Conditions
Acute Pain, Ankle Sprain
Interventions
Diclofenac Sodium, Matching Placebo Patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
17 Years to 75 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Sep 20, 2026, 10:32 PM EDT